AU2017306140A1 - Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions - Google Patents

Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions Download PDF

Info

Publication number
AU2017306140A1
AU2017306140A1 AU2017306140A AU2017306140A AU2017306140A1 AU 2017306140 A1 AU2017306140 A1 AU 2017306140A1 AU 2017306140 A AU2017306140 A AU 2017306140A AU 2017306140 A AU2017306140 A AU 2017306140A AU 2017306140 A1 AU2017306140 A1 AU 2017306140A1
Authority
AU
Australia
Prior art keywords
composition
skin
ocs
aspects
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017306140A
Other languages
English (en)
Inventor
James E. Brown
Mee Jean KIM
Min L. Lee
Weiqi Lin
Andrew R. Miksztal
Shunlin Ren
Huey-Ching Su
Wilma Tamraz
Felix Theeuwes
Hongwei WU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Durect Corp
US Department of Veterans Affairs
Original Assignee
Virginia Commonwealth University
Durect Corp
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University, Durect Corp, US Department of Veterans Affairs filed Critical Virginia Commonwealth University
Publication of AU2017306140A1 publication Critical patent/AU2017306140A1/en
Assigned to VIRGINIA COMMONWEALTH UNIVERSITY, DURECT CORPORATION, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS reassignment VIRGINIA COMMONWEALTH UNIVERSITY Amend patent request/document other than specification (104) Assignors: DURECT CORPORATION, VIRGINIA COMMONWEALTH UNIVERSITY
Priority to AU2022205208A priority Critical patent/AU2022205208A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017306140A 2016-08-02 2017-08-01 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions Abandoned AU2017306140A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022205208A AU2022205208A1 (en) 2016-08-02 2022-07-13 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370036P 2016-08-02 2016-08-02
US62/370,036 2016-08-02
US201762470576P 2017-03-13 2017-03-13
US62/470,576 2017-03-13
PCT/US2017/044821 WO2018026767A1 (en) 2016-08-02 2017-08-01 Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022205208A Division AU2022205208A1 (en) 2016-08-02 2022-07-13 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions

Publications (1)

Publication Number Publication Date
AU2017306140A1 true AU2017306140A1 (en) 2019-02-21

Family

ID=61073120

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017306140A Abandoned AU2017306140A1 (en) 2016-08-02 2017-08-01 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions
AU2022205208A Abandoned AU2022205208A1 (en) 2016-08-02 2022-07-13 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022205208A Abandoned AU2022205208A1 (en) 2016-08-02 2022-07-13 Use of oxygenated cholesterol sulfates (OCS) to treat inflammatory skin disease and skin lesions

Country Status (12)

Country Link
US (2) US20190374554A1 (enExample)
EP (1) EP3493671A4 (enExample)
JP (2) JP2019524774A (enExample)
KR (2) KR102568036B1 (enExample)
CN (1) CN109862787A (enExample)
AU (2) AU2017306140A1 (enExample)
BR (1) BR112019001193A2 (enExample)
CA (1) CA3031211A1 (enExample)
IL (1) IL264389A (enExample)
MX (1) MX2019001324A (enExample)
TW (2) TW201818944A (enExample)
WO (1) WO2018026767A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
SMT202200094T1 (it) 2013-12-24 2022-05-12 Univ Virginia Commonwealth Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta
WO2018026781A1 (en) 2016-08-02 2018-02-08 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
AU2021221109A1 (en) * 2020-02-11 2022-08-25 Durect Corporation Treatment of infectious diseases
JP2023539595A (ja) * 2020-08-26 2023-09-15 オティカラ，インコーポレーテッド 鼻、耳及び他の組織の感染症及び／又は炎症を処置するための組成物、デバイス及び方法
CN113040140B (zh) * 2021-01-28 2022-06-03 菲吉乐科(南京)生物科技有限公司 一种适合噬菌体浸入藤本和木本植物用的辅助渗透剂及其制备方法和应用
CN113521094A (zh) * 2021-05-23 2021-10-22 广州奇维生物信息技术有限公司 一种治疗湿疹的乳剂软膏及其制备方法
CN114646702B (zh) * 2022-03-03 2023-01-06 四川大学华西医院 胆固醇硫酸酯检测试剂在制备脓毒症辅助诊断、治疗效果监测和预后评估试剂盒中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4743597A (en) * 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
US20120253143A1 (en) * 2011-04-04 2012-10-04 Raphael Warren Method of measuring a skin agent transferred to skin
WO2013154752A1 (en) * 2012-04-12 2013-10-17 Virgina Commonwealth University A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS
SMT202200094T1 (it) * 2013-12-24 2022-05-12 Univ Virginia Commonwealth Uso di solfati di colesterolo ossigenati (ocs) per il trattamento dell’insufficienza epatica acuta

Also Published As

Publication number Publication date
MX2019001324A (es) 2019-07-04
KR102568036B1 (ko) 2023-08-17
AU2022205208A1 (en) 2022-08-04
CN109862787A (zh) 2019-06-07
WO2018026767A1 (en) 2018-02-08
EP3493671A1 (en) 2019-06-12
US20190374554A1 (en) 2019-12-12
CA3031211A1 (en) 2018-02-08
JP2019524774A (ja) 2019-09-05
EP3493671A4 (en) 2020-04-08
TW201818944A (zh) 2018-06-01
JP2022031733A (ja) 2022-02-22
KR20230124756A (ko) 2023-08-25
IL264389A (en) 2019-02-28
TW202308651A (zh) 2023-03-01
KR20190032530A (ko) 2019-03-27
BR112019001193A2 (pt) 2019-04-30
US20210169902A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
US20210169902A1 (en) Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
US12226423B2 (en) Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CN111904926B (zh) 局部用双氯芬酸钠组合物
JP5052558B2 (ja) ゲル軟膏
JP2021008505A (ja) コルチコステロイドを含む局所用組成物
US20120022019A1 (en) Medicinal Steroids Cream And A Process To Make It
US20120136071A1 (en) Medicinal Cream For Diaper Rash And A Process To Make It
US8673356B2 (en) Stable fixed dose topical formulation
US20120028943A1 (en) Medicinal Cream Made Using Fluticasone Propionate And Chitosan And A Process To Make The Same
CN101208096A (zh) 氯倍他索喷雾制剂在治疗银屑病中的应用
US20120270835A1 (en) Medicinal Cream Made Using Hydrocortisone Acetate and A Process To Make The Same
WO2009084020A2 (en) Topical composition comprising halobetasol and salicylic acid
US20120108539A1 (en) Medicinal Anti Acne Cream And A Process To Make It
US9731021B2 (en) Hydrogel composition for the treatment of dermatological disorders
RU2440108C2 (ru) Фармацевтическая композиция для лечения аллергических и воспалительных заболеваний кожи
WO2011027246A1 (en) A cream comprising miconazole nitrate and a biopolymer for the treatment of diaper rash
US20120035233A1 (en) Medicinal cream made using miconazole nitrate and chitosan and a process to make the same
CN115279788A (zh) 用于治疗银屑病和其他疾病的外用环孢霉素
WO2010109433A1 (en) An antiviral medicinal cream and a process to make it
CA3118698A1 (en) Teriflunomide topical pharmaceutical compositions
WO2010109432A1 (en) An antiscabies medicinal cream and a process to make it

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: VIRGINIA COMMONWEALTH UNIVERSITY

Free format text: FORMER NAME(S): VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION

Owner name: DURECT CORPORATION

Free format text: FORMER NAME(S): VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION

Owner name: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Free format text: FORMER NAME(S): VIRGINIA COMMONWEALTH UNIVERSITY; DURECT CORPORATION

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted